Effects of a Short Course of Oral Prednisolone in Patients with Bladder Pain Syndrome with Fluctuating, Worsening Pain Despite Low-Dose Triple Therapy

Overview

Journal Int Neurourol J

Date 2013 Jan 25

PMID 23346483

Citations 8

Authors

Hee Jong Jeong

Affiliations

Soon will be listed here.

Abstract

Purpose: Triple therapy with gabapentin, amitriptyline, and nonsteroidal antiinflammatory drugs is efficacious for chronic bladder pain syndrome/interstitial cystitis (BPS/IC). However, transient, fluctuating, worsening pain or flare-up symptoms may develop during treatment for a variety of reasons. Here, we assessed the validity of our observational experience regarding a short course of oral prednisolone therapy, which might be of value in the management of flare-up symptoms of BPS/IC.

Methods: Between May 2007 and May 2012, 7 women (mean age, 61.5 years; range, 44.8 to 75.4 years) with BPS/IC presenting with transient, fluctuating, worsening pain as a flare-up symptom despite low-dose triple therapy received a 1- to 3-month course of oral prednisolone 10 mg. The outcome measures used were the IC symptom scale (ICSS, O'Leary-Sant Interstitial Cystitis Symptom Index) and a visual analogue scale (VAS), which were completed at baseline and after treatment.

Results: There were statistically significant differences in the ICSS and VAS score before and after prednisolone treatment (P<0.05 by Wilcoxon singed-rank test). The pretreatment IC symptom index (ICSI), IC problem index (ICPI), and VAS score were 16.7± 2.2, 13.7±2.3, and 8.3±1.5 (mean±standard deviation [SD]), and the posttreatment scores were 4.9±2.3, 4.3±1.1, and 2.5±0.9 (mean±SD), respectively. The ICSI, ICPI, and VAS scores were improved after prednisolone treatment by 70.7%, 68.6%, and 69.9%, respectively. Low-dose triple therapy with prednisolone caused no significant adverse effects.

Conclusions: In patients with BPS/IC who show transient, fluctuating, worsening pain as flare-up symptoms despite undergoing low-dose triple therapy, a short course of oral prednisolone therapy was sufficiently effective. However, large-scale studies should be performed to verify our findings.

Citing Articles

The Pathomechanism and Current Treatments for Chronic Interstitial Cystitis and Bladder Pain Syndrome.

Yu W, Jhang J, Jiang Y, Kuo H Biomedicines. 2024; 12(9).

PMID: 39335564 PMC: 11428245. DOI: 10.3390/biomedicines12092051.

Urologic Chronic Pelvic Pain Syndrome Flares: A Comprehensive, Systematic Review and Meta-Analysis of the Peer-Reviewed Flare Literature.

Barker E, Chiu K, Brown V, Morsy H, Yaeger L, Catna A J Urol. 2023; 211(3):341-353.

PMID: 38109700 PMC: 11037930. DOI: 10.1097/JU.0000000000003820.

Management of Symptom Flares and Patient-reported Flare Triggers in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)-Findings From One Site of the MAPP Research Network.

Lai H, Vetter J, Song J, Andriole G, Colditz G, Sutcliffe S Urology. 2019; 126:24-33.

PMID: 30682464 PMC: 6874838. DOI: 10.1016/j.urology.2019.01.012.

Urological chronic pelvic pain syndrome flares and their impact: qualitative analysis in the MAPP network.

Sutcliffe S, Bradley C, Quentin Clemens J, James A, Konkle K, Kreder K Int Urogynecol J. 2015; 26(7):1047-60.

PMID: 25792349 PMC: 4489981. DOI: 10.1007/s00192-015-2652-6.

The antinociceptive effects of tualang honey in male sprague-dawley rats: a preliminary study.

Abd Aziz C, Ismail C, Che Hussin C, Mohamed M J Tradit Complement Med. 2014; 4(4):298-302.

PMID: 25379476 PMC: 4220512. DOI: 10.4103/2225-4110.139115.

References

Lee J, Han D, Jeong H . Bladder pain syndrome treated with triple therapy with gabapentin, amitriptyline, and a nonsteroidal anti-inflammatory drug. Int Neurourol J. 2011; 14(4):256-60. PMC: 3021818. DOI: 10.5213/inj.2010.14.4.256. View

Bates S, Hill V, Anderson J, Chapple C, Spence R, Ryan C . A prospective, randomized, double-blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. BJU Int. 2007; 99(2):355-9. DOI: 10.1111/j.1464-410X.2007.06667.x. View

Sant G . Etiology, pathogenesis, and diagnosis of interstitial cystitis. Rev Urol. 2006; 4 Suppl 1:S9-S15. PMC: 1476007. View

Marmura M . Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol. 2011; 14(1):27-35. DOI: 10.1007/s11940-011-0150-9. View

Giovannoni M, Ghelardini C, Vergelli C, Piaz V . Alpha2-agonists as analgesic agents. Med Res Rev. 2008; 29(2):339-68. DOI: 10.1002/med.20134. View

Minami M, Katayama T, Satoh M . Brain cytokines and chemokines: roles in ischemic injury and pain. J Pharmacol Sci. 2006; 100(5):461-70. DOI: 10.1254/jphs.crj06005x. View

Chen M, Blunt L, Pins M, Klumpp D . Tumor necrosis factor promotes differential trafficking of bladder mast cells in neurogenic cystitis. J Urol. 2006; 175(2):754-9. DOI: 10.1016/S0022-5347(05)00171-0. View

Nickel J . Opioids for chronic prostatitis and interstitial cystitis: lessons learned from the 11th World Congress on Pain. Urology. 2006; 68(4):697-701. DOI: 10.1016/j.urology.2006.04.013. View

de Leon-Casasola O . New developments in the treatment algorithm for peripheral neuropathic pain. Pain Med. 2011; 12 Suppl 3:S100-8. DOI: 10.1111/j.1526-4637.2011.01160.x. View

10.

Shibata S, Ubara Y, Sawa N, Tagami T, Hosino J, Yokota M . Severe interstitial cystitis associated with Sjögren's syndrome. Intern Med. 2004; 43(3):248-52. DOI: 10.2169/internalmedicine.43.248. View

11.

Gottschalk A, Smith D . New concepts in acute pain therapy: preemptive analgesia. Am Fam Physician. 2001; 63(10):1979-84. View

12.

Fall M, Baranowski A, Elneil S, Engeler D, Hughes J, Messelink E . EAU guidelines on chronic pelvic pain. Eur Urol. 2009; 57(1):35-48. DOI: 10.1016/j.eururo.2009.08.020. View

13.

Hanno P, Dmochowski R . Status of international consensus on interstitial cystitis/bladder pain syndrome/painful bladder syndrome: 2008 snapshot. Neurourol Urodyn. 2009; 28(4):274-86. DOI: 10.1002/nau.20687. View

14.

Hayashi R, Xiao W, Kawamoto M, Yuge O, Bennett G . Systemic glucocorticoid therapy reduces pain and the number of endoneurial tumor necrosis factor-alpha (TNFalpha)-positive mast cells in rats with a painful peripheral neuropathy. J Pharmacol Sci. 2008; 106(4):559-65. DOI: 10.1254/jphs.fp0072181. View

15.

Savidge C, Slade P . Psychological aspects of chronic pelvic pain. J Psychosom Res. 1997; 42(5):433-44. DOI: 10.1016/s0022-3999(96)00300-5. View

16.

Tfelt-Hansen P, Daugaard D, Lassen L, Iversen H, Olesen J . Prednisolone reduces nitric oxide-induced migraine. Eur J Neurol. 2009; 16(10):1106-11. DOI: 10.1111/j.1468-1331.2009.02654.x. View

17.

Eker H, Yalcin Cok O, Aribogan A . A treatment option for post-injection sciatic neuropathy: transsacral block with methylprednisolone. Pain Physician. 2010; 13(5):451-6. View